RxDoctor Payments Data

Patrick Kulubya, MD

Nephrology · Memphis, TNNPI 1720057714

Payments from drug & device makers

$2,591in general payments, 2019–2025

Across 125 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$819
  • Lilly USA, LLC$312
  • Ardelyx, Inc.$262
  • Travere Therapeutics, Inc.$211
  • Novartis$188
  • Otsuka America Pharmaceutical, Inc.$187
  • plus $612 from 12 others

What the payments were for

  • Food & beverage$2,42694%
  • Education$1656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,591 in reported general payments places this provider in the 65th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$549,777
Medicare patients
1,058
Services billed
6,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide232$576,477
VeltassaPatiromer Calcium Sorbitex64$57,192
Sevelamer Carbonate185$45,247
FarxigaDapagliflozin Propanediol56$44,250
Midodrine Hcl15$3,135
Cinacalcet Hcl44$3,066
Calcium Acetate30$2,803
Hydralazine Hcl124$1,421
Potassium Chloride80$1,045
Amlodipine Besylate144$684
Losartan Potassium90$641
Carvedilol79$588
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide20$488
Labetalol Hcl19$433
Olmesartan Medoxomil51$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$100$576,477232 claims
AstraZenecaFarxiga$51$44,25056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →